Editorial: New insights into understanding and managing NAFLD

Autores
Escribano, Óscar; Frances, Daniel Eleazar Antonio; Otero, Yolanda F.; Egea, Javier; González Rodríguez, Águeda
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease with complications related to the metabolic syndrome and with a diverse histopathological spectrum ranging from simple steatosis, also termed fatty liver (NAFL) without significant inflammation to steatohepatitis (NASH) with varying stages of fibrosis and, ultimately, cirrhosis, and hepatocellular carcinoma. Since NAFLD is the most common chronic liver disease worldwide, causing a considerable health burden, there is an increasing number of research groups that are deeply interested in the identification of risk factors involved in the progression of the liver damage, the characterization of new biomarkers with utility for its non-invasive diagnosis and the recognition of novel molecular targets for its treatment.
Fil: Escribano, Óscar. Universidad Complutense de Madrid; España
Fil: Frances, Daniel Eleazar Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; Argentina
Fil: Otero, Yolanda F.. Valbiotis; Francia
Fil: Egea, Javier. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; España
Fil: González Rodríguez, Águeda. Centro de Investigación Biomédica En Red de Diabetes y Enfermedades Metabólicas Asociadas; Argentina. Instituto de Salud Carlos III; España
Materia
BIOMARKERS
LIVER PATHOPHYSIOLOGY
NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)
STEATOHEPATITIS
THERAPEUTICAL APPROACHES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/172548
Acceder
id CONICETDig_8c1b90feb88d0023041e53b67c07113c
oai_identifier_str oai:ri.conicet.gov.ar:11336/172548
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Editorial: New insights into understanding and managing NAFLDEscribano, ÓscarFrances, Daniel Eleazar AntonioOtero, Yolanda F.Egea, JavierGonzález Rodríguez, ÁguedaBIOMARKERSLIVER PATHOPHYSIOLOGYNAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)STEATOHEPATITISTHERAPEUTICAL APPROACHEShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease with complications related to the metabolic syndrome and with a diverse histopathological spectrum ranging from simple steatosis, also termed fatty liver (NAFL) without significant inflammation to steatohepatitis (NASH) with varying stages of fibrosis and, ultimately, cirrhosis, and hepatocellular carcinoma. Since NAFLD is the most common chronic liver disease worldwide, causing a considerable health burden, there is an increasing number of research groups that are deeply interested in the identification of risk factors involved in the progression of the liver damage, the characterization of new biomarkers with utility for its non-invasive diagnosis and the recognition of novel molecular targets for its treatment.Fil: Escribano, Óscar. Universidad Complutense de Madrid; EspañaFil: Frances, Daniel Eleazar Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; ArgentinaFil: Otero, Yolanda F.. Valbiotis; FranciaFil: Egea, Javier. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; EspañaFil: González Rodríguez, Águeda. Centro de Investigación Biomédica En Red de Diabetes y Enfermedades Metabólicas Asociadas; Argentina. Instituto de Salud Carlos III; EspañaFrontiers Media2021-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/172548Escribano, Óscar; Frances, Daniel Eleazar Antonio; Otero, Yolanda F.; Egea, Javier; González Rodríguez, Águeda; Editorial: New insights into understanding and managing NAFLD; Frontiers Media; Frontiers in Medicine; 8; 11-2021; 1-32296-858XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fmed.2021.777740/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fmed.2021.777740info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:42:03Zoai:ri.conicet.gov.ar:11336/172548instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:42:03.291CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Editorial: New insights into understanding and managing NAFLD
title Editorial: New insights into understanding and managing NAFLD
spellingShingle Editorial: New insights into understanding and managing NAFLD
Escribano, Óscar
BIOMARKERS
LIVER PATHOPHYSIOLOGY
NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)
STEATOHEPATITIS
THERAPEUTICAL APPROACHES
title_short Editorial: New insights into understanding and managing NAFLD
title_full Editorial: New insights into understanding and managing NAFLD
title_fullStr Editorial: New insights into understanding and managing NAFLD
title_full_unstemmed Editorial: New insights into understanding and managing NAFLD
title_sort Editorial: New insights into understanding and managing NAFLD
dc.creator.none.fl_str_mv Escribano, Óscar
Frances, Daniel Eleazar Antonio
Otero, Yolanda F.
Egea, Javier
González Rodríguez, Águeda
author Escribano, Óscar
author_facet Escribano, Óscar
Frances, Daniel Eleazar Antonio
Otero, Yolanda F.
Egea, Javier
González Rodríguez, Águeda
author_role author
author2 Frances, Daniel Eleazar Antonio
Otero, Yolanda F.
Egea, Javier
González Rodríguez, Águeda
author2_role author
author
author
author
dc.subject.none.fl_str_mv BIOMARKERS
LIVER PATHOPHYSIOLOGY
NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)
STEATOHEPATITIS
THERAPEUTICAL APPROACHES
topic BIOMARKERS
LIVER PATHOPHYSIOLOGY
NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)
STEATOHEPATITIS
THERAPEUTICAL APPROACHES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease with complications related to the metabolic syndrome and with a diverse histopathological spectrum ranging from simple steatosis, also termed fatty liver (NAFL) without significant inflammation to steatohepatitis (NASH) with varying stages of fibrosis and, ultimately, cirrhosis, and hepatocellular carcinoma. Since NAFLD is the most common chronic liver disease worldwide, causing a considerable health burden, there is an increasing number of research groups that are deeply interested in the identification of risk factors involved in the progression of the liver damage, the characterization of new biomarkers with utility for its non-invasive diagnosis and the recognition of novel molecular targets for its treatment.
Fil: Escribano, Óscar. Universidad Complutense de Madrid; España
Fil: Frances, Daniel Eleazar Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; Argentina
Fil: Otero, Yolanda F.. Valbiotis; Francia
Fil: Egea, Javier. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; España
Fil: González Rodríguez, Águeda. Centro de Investigación Biomédica En Red de Diabetes y Enfermedades Metabólicas Asociadas; Argentina. Instituto de Salud Carlos III; España
description Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease with complications related to the metabolic syndrome and with a diverse histopathological spectrum ranging from simple steatosis, also termed fatty liver (NAFL) without significant inflammation to steatohepatitis (NASH) with varying stages of fibrosis and, ultimately, cirrhosis, and hepatocellular carcinoma. Since NAFLD is the most common chronic liver disease worldwide, causing a considerable health burden, there is an increasing number of research groups that are deeply interested in the identification of risk factors involved in the progression of the liver damage, the characterization of new biomarkers with utility for its non-invasive diagnosis and the recognition of novel molecular targets for its treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/172548
Escribano, Óscar; Frances, Daniel Eleazar Antonio; Otero, Yolanda F.; Egea, Javier; González Rodríguez, Águeda; Editorial: New insights into understanding and managing NAFLD; Frontiers Media; Frontiers in Medicine; 8; 11-2021; 1-3
2296-858X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/172548
identifier_str_mv Escribano, Óscar; Frances, Daniel Eleazar Antonio; Otero, Yolanda F.; Egea, Javier; González Rodríguez, Águeda; Editorial: New insights into understanding and managing NAFLD; Frontiers Media; Frontiers in Medicine; 8; 11-2021; 1-3
2296-858X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fmed.2021.777740/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fmed.2021.777740
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613325595344896
score 13.070432

Publicaciones similares